Skip to main content
Back
VIMGF logo

Vimian Group AB (publ)

Data quality: 100%
Overbought
VIMGF
OTC Healthcare Medical - Diagnostics & Research
$2.77
$0.00 (0.00%)
Mkt Cap: 1.46B
Day Range
$2.68 $2.77
52-Week Range
$2.68 $4.50
Volume
7,000
50D / 200D Avg
$2.77 / $3.32
Prev Close
$2.77

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E 46.6 0.3
P/B 2.1 2.9
ROE % 4.5 3.7
Net Margin % 7.4 3.8
Rev Growth 5Y % 25.1 10.0
D/E 0.3 0.2

Analyst Price Target

Hold
$42.00 +1416.2%
Forward P/E
25.6
Forward EPS
$0.11
EPS Growth (est.)
+0.0%
Est. Revenue
460 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2028 $0.15
$0.15 – $0.15
 550 M 1
FY2027 $0.13
$0.13 – $0.13
 500 M 1
FY2026 $0.11
$0.11 – $0.11
 460 M 1

Key Takeaways

Revenue grew 25.13% annually over 5 years — strong growth
Earnings grew 69.19% over the past year
ROE of 4.48% is below average
Debt/Equity of 0.34 — conservative balance sheet
Generating 90.60M in free cash flow
P/E of 46.55 — premium valuation

Growth

Revenue Growth (5Y)
25.13%
Revenue (1Y)13.39%
Earnings (1Y)69.19%
FCF Growth (3Y)N/A

Quality

Return on Equity
4.48%
ROIC5.89%
Net Margin7.36%
Op. Margin17.32%

Safety

Debt / Equity
0.34
Current Ratio1.95
Interest Coverage3.49

Valuation

P/E Ratio
46.55
P/B Ratio2.08
EV/EBITDA22.29
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 13.39% Revenue Growth (3Y) 13.19%
Earnings Growth (1Y) 69.19% Earnings Growth (3Y) 78.35%
Revenue Growth (5Y) 25.13% Earnings Growth (5Y) 47.65%
Profitability
Revenue (TTM) 425.00M Net Income (TTM) 31.30M
ROE 4.48% ROA 2.82%
Gross Margin 68.89% Operating Margin 17.32%
Net Margin 7.36% Free Cash Flow (TTM) 90.60M
ROIC 5.89% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.34 Current Ratio 1.95
Interest Coverage 3.49 Dividend Yield 0.00%
Valuation
P/E Ratio 46.55 P/B Ratio 2.08
P/S Ratio 3.43 PEG Ratio 0.55
EV/EBITDA 22.29 Dividend Yield 0.00%
Market Cap 1.46B Enterprise Value 1.64B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 425.00M 374.80M 331.73M 281.31M 173.35M
Net Income 31.30M 18.50M 9.84M -7.20M 6.59M
EPS (Diluted) 0.06 0.04 0.02 -0.02 0.02
Gross Profit 292.80M 258.30M 229.43M 193.99M 122.85M
Operating Income 73.59M 49.20M 41.27M 39.36M 21.60M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.11B 1.11B 973.68M 923.56M 640.72M
Total Liabilities 401.00M 403.30M 446.97M 442.06M 282.08M
Shareholders' Equity 698.90M 699.90M 526.37M 481.81M 357.41M
Total Debt 238.70M 233.60M 313.80M 220.96M 180.37M
Cash & Equivalents 55.00M 64.80M 37.50M 42.19M 55.11M
Current Assets 213.50M 222.70M 158.94M 206.69M 131.47M
Current Liabilities 109.40M 109.90M 74.89M 166.26M 72.69M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#638 of 1052
39

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026